HepQuant is currently working with major pharmaceutical companies and leading academic researchers in clinical trials, to test levels of hepatic impairment, under the Investigational Device Exemption (IDE) mechanism with the FDA. We have invested in infrastructure, regulatory, and operations to offer kit production and laboratory analysis compliant with the FDA IDE regulations and deliver results. If you are interested in working with us, please contact Brad Everson.
Hepatic Testing for Liver Disease Clinical Trials and Research
Our tests measure hepatic blood flow, portal blood flow, and portal-systemic shunt in patients with chronic liver disease. The tests are designed to evaluate the liver — and levels of hepatic impairment — regardless of the etiology of the liver disease. HepQuant provides liver testing support services to liver research centers and pharmaceutical companies.
These services include:
- Consultative Services – Analysis and assessments of research applications of HepQuant tests
- Lab Services – Processing and analysis of serum samples
- Modeling and Reporting Services – Analysis of data and relationship to utility and outcomes
If your organization is interested in learning more about our services and how they might match up with your core competencies, please connect with us via our contact us page.
HepQuant’s Lab Team includes, from left: Keith Hoffman (Clinical Lab Manager), Koren Newman (Laboratory QA Specialist), Steve Helmke (Chief Scientific Officer), and Dziuleta Cepeniene (Laboratory Operations Manager). HepQuant’s Lab is located at 12635 E. Montview Blvd., Suite 175, Aurora, CO 80045.